Valion Bio
VBIO
4 hedge funds and large institutions have $104K invested in Valion Bio in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
68% less capital invested
Capital invested by funds: $329K → $104K (-$225K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.93K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$147K |
| 2 |
KC
Kepos Capital
New York
|
-$97K |
| 3 |
BlackRock
New York
|
-$15K |
| 4 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $73K | -$147K | -50 | -69% |
|
2
Osaic Holdings
Scottsdale,
Arizona
| $17K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $10K | +$2.93K | +1 | +50% |
|
|
4
UBS Group
Zurich,
Switzerland
| $4K | +$2.93K | +1 | New |
|
|
KC
5
Kepos Capital
New York
| – | -$97K | -35 | Closed |
|
|
6
BlackRock
New York
| – | -$15K | -6 | Closed |
|
|
TFS
7
TrustCore Financial Services
Brentwood,
Tennessee
| – | -$1K | – | – |
|
VBIO Hedge Fund Activity: Q2 2022 in Review
4 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2022, worth a combined $104K — down 68% from $329K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VBIO and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.93K. The largest seller was Renaissance Technologies, cutting an estimated $147K.
- 4 institutional investors held Valion Bio (VBIO) as of Q2 2022, down from 5 in Q1 2022.
- Funds reported $104K of Valion Bio stock for Q2 2022, down 68% quarter-over-quarter.
- 1 fund opened new Valion Bio positions in Q2 2022 and 2 closed out, a net change of -1 holder.
- The largest Valion Bio buyer in Q2 2022 was Tower Research Capital (TRC), an estimated $2.93K added.
- The largest Valion Bio seller in Q2 2022 was Renaissance Technologies, an estimated $147K sold.
Based on aggregated 13F filings for Q2 2022.